Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma. Issue 24 (2nd November 2021)

• Record Type: Journal Article
• Authors: Lai, Enjiang; Tai, Yang; Jiang, Jingsun; Zhao, Chong; Xiao, Yang; Quan, Xin; Wu, Hao; Gao, Jinhang
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 24(2021)
• Page Start: 11128
• Page End: 11141
• Publication Date: 2021-11-02
• Subjects: bioinformatics -- cell proliferation -- hepatocellular carcinoma -- immune infiltration -- prognosis; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.17035
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Despite the development in hepatocellular carcinoma (HCC) treatment in recent years, the therapeutic outcome of HCC remains unfavourable. This study examines the prognosis of HCC from a genetic level using clinical databases and single‐cell data to identify genes with a high prognostic value. Three up‐regulated genes ( UBE2S, PTTG1, and CDC20 ) and two down‐regulated genes ( SOCS2 and DNASE1L3 ) in HCC tissues were identified. Various analyses confirmed its correlation with tumour stage ( p < 0.01) and patient survival time (log‐rank p < 0.001). Immune analysis, single‐cell analysis, and gene set enrichment analysis (GSEA) were employed to provide insight on how they affect cancer progression, and we observed a close relation between these genes and tumour immune infiltration. Eventually, we constructed a risk score system that risk score = (0.0465) × UBE2S + (0.1851) × CDC20 + (−0.0461) × DNASE1L3 + (−0.2279) × SOCS2 (5‐year area under curve = 0.706). The risk score system may serve as an effective novel prognostic system for HCC patients. This study might provide novel ideas for prognostic or therapeutic biomarkers for HCC.